Nascent Biotech Presents at the July Emerging Growth Conference

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) presented at the Emerging Growth Conference on July 18, 2024, highlighting its progress in developing Pritumumab (PTB), a monoclonal antibody targeting various cancer types. CEO Sean Carrick discussed:

1. PTB's successful Phase I results and safety profile
2. Plans for Phase II trials focusing on brain cancer, with potential expansion to pancreatic and colorectal cancers
3. Timeline for manufacturing completion by year-end and Phase II trials starting in Q1 2025
4. The company's de-risked investment profile and need for funding to advance clinical trials

Nascent aims to begin expanded access trials for digestive cancers in Q2 2025, leveraging PTB's potential across multiple cancer types.

Positive

• Successful completion of Phase I trials for Pritumumab (PTB), demonstrating safety across five ascending dose cohorts
• FDA clearance to begin Phase II trials for brain cancer
• Potential expansion into pancreatic ($6.85B market) and colorectal ($26B market) cancer treatments
• Orphan Drug Designation for pancreatic cancer
• Case studies showing significant tumor shrinkage and improved quality of life in patients

Negative

• Need for additional funding to proceed with Phase II trials and expanded access studies
• Dependence on successful manufacturing completion by year-end to start Phase II trials in Q1 2025

Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company

NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, is pleased to provide an overview of the Company's presentation at The Emerging Growth Conference on July 18, 2024.

Click here to view the Company's entire presentation.

NBIO CEO, Sean Carrick, and other Biotechnology Innovators, were interviewed during the Emerging Biotechnology in a discussion lasting over 20 minutes.

Topics covered by Mr. Carrick included:

• The history of NBIO and its lead asset, Pritumumab (PTB),

• How PTB is being leveraged to target brain cancer first, with other cancer types to follow, including the $6.85 Bln Pancreatic Cancer market and the $26 Bln Colorectal Cancer market,

• Clinical research results for PTB's concluded Phase I study,

• The timeline and outlook for coming clinical research,

• The opportunity NBIO presents for prospective investors given its de-risked investment profile.

The Emerging Growth Conference describes itself as an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

Mr. Carrick's presentation included a number of important ideas covering the Company and the opportunity it presents for investors, including:

Company History and Development

• Nascent Biotech's its lead antibody was originally developed in the early 1980's in San Diego, California

• The antibody, derived from a cancer patient, showed binding to various cancer types, including brain cancer.

• Development continued in Japan, where Phase I and phase II trials were conducted, showing biological activity in brain cancer.

U.S. Development and Phase I Trials

• The antibody was brought back to the U.S., re-engineered, and underwent pre-clinical work.

• Phase I trials in the U.S. were completed a year ago and cleared to begin Phase II.

Focus on Brain Cancer

• Brain cancer was chosen due to previous successful studies in Japan.

• The target that PTB has an affinity for is shown to be present in virtually every hard tumor cancer, suggesting potential for broader applications.

• Nascent plans include opening a second expanded access study to test PTB in other cancer types during Phase II.

Phase I Results

• Nascent's U.S. Phase I trial was shown to be very safe at five ascending dose cohorts.

• Highlighted case studies showed significant tumor shrinkage and improved quality of life in patients.

Phase II Study Design

• Phase II studies have been cleared by the FDA to begin.

• The study will include monotherapy, combination with chemotherapy, and combination with checkpoint inhibitors for recurrent glioblastomas with an additional arm focusing on newly diagnosed glioblastomas prior to chemo-radiation treatment.

• Expanded access trials will focus on digestive cancers including pancreatic-which Nascent has Orphan Drug Designation for-and colon cancers due to their growing incidence.

Plans and Timelines

• Manufacturing is expected to be completed by the end of the year, with Phase II trials beginning in Q1 of next year.

• An expanded access trial to treat other cancers is planned for Q2.

• The company emphasizes the need for funding to achieve these goals.

Management Team and Investment Opportunity

• The management team is experienced and accomplished, with backgrounds in life sciences, cancer research, and corporate financing.

• The lead asset (PTB) has shown safety in Phase I trials and is cleared for Phase II.

• The company is fully reporting and has a history of timely filings for over 10 years.

In his closing comments, Mr. Carrick remarked, "This is a very important drug. Two independent studies have shown PTB to be safe and demonstrated its potential to shrink difficult to treat brain tumors. We have seen PTB shrink Tumors in early trials and are excited to begin Phase II, but we do need investment dollars in order to make that happen."

ABOUT NASCENT

Nascent Biotech, Inc. (OTCQB:NBIO) is a phase 2 clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers, helping people worldwide. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact

Sean Carrick | President | CEO | Nascent Biotech, Inc.
sean.carrick@nascentbiotech.com

Public Relations

EDM Media, LLC https://edm.media

SOURCE: Nascent Biotech Inc.

View the original press release on accesswire.com

FAQ

What are the main focus areas for Nascent Biotech's Pritumumab (PTB) in Phase II trials?

Nascent Biotech's Phase II trials for Pritumumab (PTB) will focus on recurrent glioblastomas using monotherapy, combination with chemotherapy, and combination with checkpoint inhibitors. An additional arm will target newly diagnosed glioblastomas prior to chemo-radiation treatment.

When does Nascent Biotech (NBIO) plan to start its Phase II trials for Pritumumab?

Nascent Biotech (NBIO) plans to start Phase II trials for Pritumumab in Q1 2025, following the expected completion of manufacturing by the end of 2024.

What markets is Nascent Biotech (NBIO) targeting with Pritumumab beyond brain cancer?

Beyond brain cancer, Nascent Biotech (NBIO) is targeting the $6.85 billion pancreatic cancer market and the $26 billion colorectal cancer market with Pritumumab.

What were the key findings from Nascent Biotech's (NBIO) Phase I trials of Pritumumab?

Nascent Biotech's (NBIO) Phase I trials of Pritumumab demonstrated that the drug was very safe across five ascending dose cohorts. Case studies showed significant tumor shrinkage and improved quality of life in patients.